错配修复缺陷型癌症是抗 PD-1 治疗的靶点。

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.

机构信息

Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

出版信息

Cancer Cell. 2015 Jul 13;28(1):11-3. doi: 10.1016/j.ccell.2015.06.012.

DOI:10.1016/j.ccell.2015.06.012

Abstract

Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of sensing the consequences of DNA damage in cancer immunotherapy.

摘要

免疫检查点阻断疗法在一系列人类恶性肿瘤中产生了积极的临床数据。最近，Le 及其同事的研究工作强烈支持这些疗法在错配修复缺陷型肿瘤中的应用，而与基础肿瘤类型无关。这些数据表明，在癌症免疫治疗中感知 DNA 损伤后果的重要性。